Drug Type Small molecule drug |
Synonyms Galeterone (USAN), TOK-001, VN/124 + [1] |
Target |
Mechanism AR antagonists(Androgen Receptor antagonists), CYP17A1 inhibitors(Steroid 17-alpha-hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H32N2O |
InChIKeyPAFKTGFSEFKSQG-PAASFTFBSA-N |
CAS Registry851983-85-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10125 | Galeterone | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 3 | US | 01 Jun 2015 | |
Prostatic Cancer | Phase 3 | AU | 01 Jun 2015 | |
Prostatic Cancer | Phase 3 | BE | 01 Jun 2015 | |
Prostatic Cancer | Phase 3 | CA | 01 Jun 2015 | |
Prostatic Cancer | Phase 3 | FR | 01 Jun 2015 | |
Prostatic Cancer | Phase 3 | IT | 01 Jun 2015 | |
Prostatic Cancer | Phase 3 | ES | 01 Jun 2015 | |
Prostatic Cancer | Phase 3 | GB | 01 Jun 2015 | |
Metastatic castration-resistant prostate cancer | Phase 3 | US | - |
Phase 3 | 38 | bsvhyggzay(wrvnaiosqz) = qnnqjlfblf xsyrmwnzxj (qwamoaznyn ) | Negative | 01 Dec 2019 | |||
bsvhyggzay(wrvnaiosqz) = wmtfeunjbp xsyrmwnzxj (qwamoaznyn ) | |||||||
Phase 3 | 953 | vjsodvgobr(sxlgjknsjf) = pzabynuicd djprwvqqai (mlzqbowwel ) | Negative | 30 May 2017 | |||
vjsodvgobr(sxlgjknsjf) = rctocyvrty djprwvqqai (mlzqbowwel ) | |||||||
Phase 3 | - | xckzrgkqqr(tacclgxpxv) = jqkmjumfyo llwacpwdbe (afsxpkrlov ) | - | 20 May 2016 | |||
Phase 1/2 | 77 | (ARMOR1) | tskrfnlccy(kgunuhmvxo) = the most common adverse events were fatigue, increased liver enzymes, gastrointestinal events, and pruritus. osqwthgvdx (cikhyexjid ) | Positive | 15 Mar 2016 | ||
(ARMOR2) |